Passage Bio, Inc.
PASG · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.02 | 0.02 | -0.09 |
| FCF Yield | -140.12% | -141.81% | -164.40% | -45.03% |
| EV / EBITDA | -0.36 | -0.61 | -0.51 | -1.14 |
| Quality | ||||
| ROIC | -81.16% | -71.04% | -59.72% | -57.05% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.74 | 0.77 | 0.87 | 0.68 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 38.80% | 36.50% | 19.04% | -85.63% |
| Safety | ||||
| Net Debt / EBITDA | 0.20 | -0.05 | 0.06 | 0.70 |
| Interest Coverage | 0.00 | 0.00 | -60.99 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -87.90 | -127.32 | -403.30 | -2,234.94 |